[ad_1]
PHOENIX (KSAZ) – In a recent study, a group of researchers tested a new melanoma vaccine.
Melanoma is the most deadly type of skin cancer. According to the American Cancer Society, more than 9,000 people die each year from the disease. Researchers at the Scripps Research Institute in California and at the University of Texas Southwestern Medical Center have researched drugs with more than 100,000 compounds.
Through tests, they found one that stimulated the immune system in mice.
"It strikes a protein on the surface of these cells that is traditionally there for infections," said Steven Albert Johnston of the Biodesign Center for Innovations in Medicine. "So when you get an infection and it stimulates this receptor on the cell, it tells the cells that foreign substances that we react to better react and stimulate the immune system."
The adjuvant compound, called diprovocim, was tested with anti-cancer drug Anti Pd L1 and another compound. The test showed a 100% success rate in the treatment of melanoma in mice.
"There is a lot of interest in taking these checkpoint inhibitors that revolutionize cancer treatment, like Pd1, and combining them with something else," Johnston said.
But it will take time to see how this new cancer vaccine can affect humans, but there is another step in the right direction, since Johnston and his ASU team are working to get an early detection diagnosis melanoma. of blood.
"We collected samples from a large study of women who were diagnosed very early with melanoma, but blood samples were taken up to two years before being diagnosed. So we are trying to see if we can still detect, "said Johnston." They were diagnosed six months earlier. We have no trouble detecting that they had Melamona. "
[ad_2]
Source link
